Clinical Trial Update: AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating allogeneic expanded human mesenchymal stem cell therapy for acute respiratory distress syndrome in patients recovering from COVID-19 ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Allogeneic Expanded Human MSC Therapy (allogeneic mesenchymal stem cells)

Snippet

Sponsor: BioCardia, Inc. | Conditions: ARDS, Human | Phase 1 | Status: WITHDRAWN